MX2023008028A - Anticuerpos anti-pd-l1 y proteinas de fusion de estos. - Google Patents

Anticuerpos anti-pd-l1 y proteinas de fusion de estos.

Info

Publication number
MX2023008028A
MX2023008028A MX2023008028A MX2023008028A MX2023008028A MX 2023008028 A MX2023008028 A MX 2023008028A MX 2023008028 A MX2023008028 A MX 2023008028A MX 2023008028 A MX2023008028 A MX 2023008028A MX 2023008028 A MX2023008028 A MX 2023008028A
Authority
MX
Mexico
Prior art keywords
antibodies
fusion proteins
sialidase
antibody conjugates
antibody
Prior art date
Application number
MX2023008028A
Other languages
English (en)
Spanish (es)
Inventor
Li Peng
Lihui Xu
Jenny Che
Original Assignee
Palleon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palleon Pharmaceuticals Inc filed Critical Palleon Pharmaceuticals Inc
Publication of MX2023008028A publication Critical patent/MX2023008028A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023008028A 2021-01-06 2022-01-06 Anticuerpos anti-pd-l1 y proteinas de fusion de estos. MX2023008028A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163134412P 2021-01-06 2021-01-06
PCT/US2022/011504 WO2022150521A1 (en) 2021-01-06 2022-01-06 Anti-pd-l1 antibodies and fusion proteins thereof

Publications (1)

Publication Number Publication Date
MX2023008028A true MX2023008028A (es) 2023-08-14

Family

ID=82357548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008028A MX2023008028A (es) 2021-01-06 2022-01-06 Anticuerpos anti-pd-l1 y proteinas de fusion de estos.

Country Status (10)

Country Link
US (1) US20240067729A1 (https=)
EP (1) EP4274614A4 (https=)
JP (1) JP2024501771A (https=)
KR (1) KR20230131236A (https=)
CN (1) CN116829188A (https=)
AU (1) AU2022206264A1 (https=)
CA (1) CA3173557A1 (https=)
IL (1) IL304190A (https=)
MX (1) MX2023008028A (https=)
WO (1) WO2022150521A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022006492A2 (en) * 2020-07-03 2022-01-06 Palleon Pharmaceuticals Inc. Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same
WO2022150516A1 (en) * 2021-01-06 2022-07-14 Palleon Pharmaceuticals Inc. Sialidase-her2-antibody fusion proteins and methods of use thereof
CN120779021A (zh) * 2024-04-08 2025-10-14 菲鹏生物股份有限公司 抗体缀合物及其用途
WO2026037175A1 (zh) 2024-08-16 2026-02-19 上海宝济药业股份有限公司 靶向靶细胞的复合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148763A (en) * 2006-03-10 2013-05-31 Wyeth Corp Anti-5t4 antibodies and uses thereof
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
CA2904969C (en) * 2013-03-13 2025-06-17 Imaginab, Inc. DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8
CN108112254B (zh) * 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
WO2016160792A1 (en) * 2015-03-30 2016-10-06 Stcube & Co., Inc. Antibodies specific to glycosylated pd-l1 and methods of use thereof
WO2018231661A1 (en) * 2017-06-12 2018-12-20 Tianxin Wang Methods and reagents to treat tumor and cancer
CN115925943A (zh) * 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
KR102914621B1 (ko) * 2018-01-03 2026-01-21 팔레온 파마슈티칼스 인크. 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법
EP3569618A1 (en) * 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
CN111606995B (zh) * 2019-06-04 2021-02-12 优睿赛思(武汉)生物科技有限公司 抗人pd-l1单克隆抗体及其应用
CN111763259B (zh) * 2020-09-03 2020-12-15 北京百奥赛图基因生物技术有限公司 抗cd40抗体及其用途

Also Published As

Publication number Publication date
WO2022150521A1 (en) 2022-07-14
IL304190A (en) 2023-09-01
AU2022206264A1 (en) 2023-07-20
CA3173557A1 (en) 2022-07-14
KR20230131236A (ko) 2023-09-12
JP2024501771A (ja) 2024-01-15
US20240067729A1 (en) 2024-02-29
EP4274614A4 (en) 2025-06-18
CN116829188A (zh) 2023-09-29
EP4274614A1 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
MX2023008028A (es) Anticuerpos anti-pd-l1 y proteinas de fusion de estos.
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
PH12021500051A1 (en) Cd3 antigen binding fragments and compositions comprising same
EA201401134A1 (ru) Hla-рестиктированные пептидоспецифические антигенсвязывающие белки
CY1123752T1 (el) Πρωτεϊνες δεσμευσης ιντερλευκινης-13
MX2009008143A (es) Antienos multivariables acomplejados con anticuerpo monoclonal humanizado de apuntamiento.
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
WO2016154047A3 (en) Monoclonal antigen-binding proteins to intracellular oncogene products
MX2023002331A (es) Anticuerpo biespecifico anti factor de crecimiento endoteliar vascular (vegf) y anti ligando 1 de la muerte programada 1 (pd-l1), composicion farmaceutica y usos del mismo.
ZA202203460B (en) Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap)
BR112022001733A2 (pt) Anticorpos anti-ms4a4a e métodos de uso dos mesmos
PH12022552520A1 (en) Antibodies binding siglec15 and uses thereof
MX2022014790A (es) Receptores de antígenos quiméricos específicos de p95her2 y usos de estos.
MX2022002672A (es) Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
WO2020223392A3 (en) Cancer associated antibody compositions and methods of use
ZA202408388B (en) Antibodies targeting sirp-alpha and uses thereof
ZA202308896B (en) Antibodies binding trop2 and uses thereof
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.
IL319054A (en) Antibodies and antibody fragments to auristatin monomethyl
MX2023008027A (es) Proteinas de fusion de sialidasa y anticuerpo her2 y metodos de uso de estas.
MX2024007035A (es) Anticuerpos anti-cdh6 y conjugados anticuerpo-farmaco de los mismos.
WO2023159187A3 (en) Anti-sars-cov2 spike (s) antibodies and uses thereof
MX2024009292A (es) Anticuerpos anti-her2/trop2 y usos de los mismos.
MX2022003191A (es) Terapias de combinacion con anticuerpos entpd2 y cd73.